Brief: U.S. FDA Grants RMAT Designation To Galapagos' GLPG5101
06/08/2025 06:32
Aug 6 (Reuters) - Galapagos NV GLPG.AS: GALAPAGOS NV - ANNOUNCES U.S. FDA REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION GRANTED TO GLPG5101 FOR TREATMENT OF RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA Source text: ID:nGNE3dtjXM Further company coverage: GLPG.AS (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 587 785 110;))
Recent news on Lakefront Biotherapeutics NV
See all newsBrief: Lakefront Announces Sale Of Preclinical Car-T Programs To Armed Cell Therapeutics
RBC upgrades Lakefront Biotherapeutics to 'outperform' on gamgertamig prospect
Brief: U.S. FDA Grants Orphan Drug Designation To Gamgertamig For The Treatment Of Pemphigus
Brief: Lakefront Biotherapeutics H1 Net Profit From Continuing Operations €15.8 Mln
Brief: Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline